Advances in drugs and genetic pharmacology for heart failure

doi:10.12092/j.issn.1009-2501.2019.03.018

Abstract

Abstract:

Heart failure (HF) is called cardiac insufficiency and mainly manifested in abnormal changes in cardiac structure and function such as ventricular systolic and (or) diastolic dysfunction, characteristic of sympathetic nerve and renin-angiotensin-aldosterone system activation. Clinical observation has showed that there was great heterogeneity in patients with HF during drug treatment. Therefore, we should take into account not only environmental factors but also genetic ones in terms of drug use, especially the epigenetics. Recently, some reports admited that the drug response of patients with HF was partly related to epigenetic modifications such as DNA methylation, histone modifications and microRNAs. But the relevant research is still rare as yet. Therefore, this article reviews the advances of epigenetic pharmacology in the treatment of HF in recent years.

Key words: heart failure, epigenetics, DNA methylation, histone modification, microRNA

CLC Number:

R541

SHEN Lei, WANG Keke, YANG Jingke, ZHAO Juntao, MENG Xiangguang, YUAN Yiqiang. Advances in drugs and genetic pharmacology for heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 343-349.

References

［1］张健, 张宇辉. 多中心、前瞻性中国心力衰竭注册登记研究—病因、临床特点和治疗情况初步分析［J］. 中国循环杂志,2015, 30(5): 413-416.
［2］Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC［J］. Eur J Heart Fail,2016, 18(8): 891-975.
［3］Mottet F, Vardeny O, de Denus S. Pharmacogenomics of heart failure: a systematic review［J］. Pharmacogenomics, 2016,17(16): 1817-1858.
［4］Kaufman AL, Spitz J, Jacobs M, et al. Evidence for clinical implementation of pharmacogenomics in cardiac drugs［J］. Mayo Clin Proc, 2015,90(6): 716-729.
［5］Iyngkaran P, Thomas MC, Johnson R, et al. Contextualizing genetics for regional heart failure care［J］. Curr Cardiol Rev,2016,12(3): 231-242.
［6］Pepin ME, Ha CM, Crossman DK, et al. Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure［J］. Lab Invest, 2018, 99(3):371-386.
［7］Schiano C, Vietri MT, Grimaldi V, et al. Epigenetic-related therapeutic challenges in cardiovascular disease［J］.Trends Pharmacol Sci,2015,36(4): 226-35.
［8］Veland N, Lu Y, Hardikar S, et al. DNMT3L facilitates DNA methylation partly by maintaining DNMT3A stability in mouse embryonic stem cells［J］.Nucleic Acids Res, 2018, 47(1):152-167.
［9］Napoli C, Grimaldi V, De Pascale MR, et al. Novel epigenetic-based therapies useful in cardiovascular medicine［J］. World J Cardiol,2016, 8(2): 211-219.
［10］Wu LX, Wen CJ, Li Y, et al. Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects［J］. Br J Clin Pharmacol,2015,80(5): 1109-1121.
［11］Thome JG, Mendoza MR, Cheuiche AV, et al. Circulating microRNAs in obese and lean heart failure patients: A case-control study with computational target prediction analysis［J］. Gene，2015， 574(1):1-10.
［12］Gonzalez-Fierro A, Vasquez-Bahena D, Taja-Chayeb L, et al. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype［J］. Int J Clin Pharmacol Ther, 2011,49(8): 519-524.
［13］Sabia C, Picascia A, Grimaldi V, et al.The epigenetic promise to improve prognosis of heart failure and heart transplantation［J］. Transplant Rev (Orlando),2017,31(4): 249-56.
［14］Yerra VG, Advani A. Histones and heart failure in diabetes［J］. Cell Mol Life Sci, 2018, 75(17):3193-3213.
［15］Reddy MA, Sumanth P, Lanting L, et al. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice［J］.Kidney Int，2014，85(2): 362-373.
［16］Sunagawa Y, Funamoto M, Sono S, et al.Curcumin and its demethoxy derivatives possess p300 HAT inhibitory activity and suppress hypertrophic responses in cardiomyocytes［J］. J Pharmacol Sci,2018,136(4): 212-217.
［17］Ghosh AK, Rai R, Flevaris P, et al.Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy［J］.J Cell Physiol，2017，232(8): 1941-1956.
［18］曾振华, 刘建新, 曹春芽, 等. 硝酸甘油耐受大鼠主动脉差异microRNA筛选与生物信息学分析［J］. 中国临床药理学与治疗学，2018，23(10): 1081-1087.
［19］Tounsi N, Trabelsi I, Kerkeni E, et al. ABCB1 and SLCO1B3 gene polymorphisms and their impact on digoxin pharmacokinetics in atrial fibrillation patients among the tunisian population［J］. Pharmacology，2017，99(5/6):250-258.
［20］Kadokura T, Groenendaal D, Heeringa M, et al. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin［J］.Eur J Drug Metab Pharmacokinet,2014,39(1): 1-9.
［21］付孟龙, 周宏灏. MDR1基因多态性及其临床相关性［J］.中国临床药理学与治疗学, 2016, 21(4): 463-469.
［22］Jiang Z, Wei C, Sun Z, et al. A simple and sensitive gas chromatography method for determination of isosorbide dinitrate and its metabolites in human plasma: application to pharmacokinetics study on oral spray［J］. Drug Res (Stuttg), 2014, 64(2): 73-78.
［23］Xu J, Huang Z, Lin L, et al. miRNA-130b is required for the ERK/FOXM1 pathway activation-mediated protective effects of isosorbide dinitrate against mesenchymal stem cell senescence induced by high glucose［J］.Int J Mol Med, 2015, 35(1): 59-71.
［24］Kao YH, Cheng CC, Chen YC, et al. Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes［J］. Lab Invest,2011,91(9): 1291-1297.
［25］Benge CD, Muldowney JA, 3rd. The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population［J］. Expert Opin Drug Metab Toxicol, 2012, 8(11): 1469-1482.
［26］Kadakol A, Malek V, Goru SK, et al.Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications［J］. Indian J Pharmacol,2017,49(5): 348-56.
［27］King AD, Huang K, Rubbi L, et al. Reversible Regulation of Promoter and Enhancer Histone Landscape by DNA Methylation in Mouse Embryonic Stem Cells［J］. Cell Rep, 2016, 17(1): 289-302.
［28］Zhu X, Li Q, Chang R, et al. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model［J］. PLoS One,2014,9(3): e91303.
［29］Jankun J, Wyganowska-Swiatkowska M, Dettlaff K, et al.Determining whether curcumin degradation/condensation is actually bioactivation (Review) ［J］. Int J Mol Med, 2016,37(5): 1151-1158.
［30］Rahman AF, Angawi RF, Kadi AA. Spatial localisation of curcumin and rapid screening of the chemical compositions of turmeric rhizomes (Curcuma longa Linn.) using Direct Analysis in Real Time-Mass Spectrometry (DART-MS) ［J］. Food Chem, 2015, 173: 489-494.
［31］Cao Q, Zhang J, Gao L, et al.Dickkopf3 upregulation mediates the cardioprotective effects of curcumin on chronic heart failure［J］. Mol Med Rep, 2018, 17(5): 7249-7257.
［32］Parker BM, Rogers SL, Lymperopoulos A. Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle［J］.Pharmacogenomics,2018,19(14): 1089-1093.
［33］Nikolic VN, Jankovic SM, Deljanin-Ilic M, et al. Population pharmacokinetic analysis of bisoprolol in patients with stable coronary artery disease［J］. Eur J Drug Metab Pharmacokinet,2018,43(1): 35-44.
［34］Sucharov CC, Kao DP, Port JD, et al. Myocardial microRNAs associated with reverse remodeling in human heart failure［J］.JCI Insight,2017, 2(2): e89169.
［35］Kim IM, Wang Y, Park KM, et al. beta-arrestin1-biased beta1-adrenergic receptor signaling regulates microRNA processing［J］. Circ Res,2014,114(5): 833-844.
［36］Teoh JP, Bayoumi AS, Aonuma T, et al. beta-arrestin-biased agonism of beta-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling［J］. J Mol Cell Cardiol, 2018, 118: 225-236.
［37］Tomaniak M, Sygitowicz G, Blaszczyk O, et al. miR-1, miR-21, and galectin-3 in hypertensive patients with symptomatic heart failure and left ventricular hypertrophy［J］. Kardiol Pol, 2018,76(6): 1009-1011.
［38］Yu HD, Xia S, Zha CQ, et al. Spironolactone regulates HCN protein expression through micro-rna-1 in rats with myocardial infarction［J］. J Cardiovasc Pharmacol,2015,65(6): 587-592.
［39］Luo S, Chen Y, He R, et al. Rescuing infusion of miRNA-1 prevents cardiac remodeling in a heart-selective miRNA deficient mouse［J］. Biochem Biophys Res Commun,2018, 495(1): 607-613.
［40］Li X, Zhang X, Wang T, et al. Regulation by bisoprolol for cardiac microRNA expression in a rat volume-overload heart failure model［J］. J Nanosci Nanotechnol, 2013, 13(8): 5267-5275.
［41］Brater DC. Update in diuretic therapy: clinical pharmacology［J］.Semin Nephrol,2011,31(6): 483-494.
［42］Stillitano F, Lonardo G, Zicha S, et al. Molecular basis of funny current (If) in normal and failing human heart［J］. J Mol Cell Cardiol,2008, 45(2): 289-299.
［43］Yang L, Wang B, Zhou Q, et al. MicroRNA-21 prevents excessive inflammation and cardiac dysfunction after myocardial infarction through targeting KBTBD7［J］.Cell Death Dis, 2018, 9(7): 769.
［44］Chimenti I, Pagano F, Cavarretta E, et al. Beta-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells［J］. Sci Rep, 2016, 6: 36774.
［45］Adam O, Zimmer C, Hanke N, et al. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice［J］. J Mol Cell Cardiol,2015, 85: 140-150.
［46］鲁秀玲, 高玉梅, 赵志刚. 血管紧张素转换酶抑制剂的研究与临床应用［J］. 药品评价,2010, 7(24): 29+32-5+9.
［47］Rana I, Velkoska E, Patel SK, et al.MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury［J］. Am J Physiol Renal Physiol,2015,309(11): F943-954.
［48］Satoh M, Takahashi Y, Tabuchi T, et al. Circulating Toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin-angiotensin system blockade［J］. Clin Sci (Lond),2015,128(8): 483-491.
［49] Rawal S, Manning P, Katare R. Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease［J］. Cardiovasc Diabetol,2014, 13: 44.
［50］Morine KJ, Qiao X, York S, et al. Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure［J］.Circulation, 2018,138(5):513-526.
［51］Kapur NK, Qiao X, Paruchuri V, et al. Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload［J］.J Am Heart Assoc,2014, 3(4).
［52］Shyu KG, Wang BW, Cheng WP, et al. MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction［J］.Can J Cardiol, 2015, 31(5): 679-690.
［53］Rieger JK, Reutter S, Hofmann U, et al. Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9［J］. Drug Metab Dispos,2015, 43(6):884-888.

[1]	LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua. Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.
[2]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[3]	PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua. Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
[4]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[5]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[6]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[7]	LIU Ping, QIU Bo, WU Huizhen. Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 212-218.
[8]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[9]	PENG Fusheng, HUANG Xiaohui, LI Peng, TANG Jian'er. miR-34a inhibits proliferation of prostate cancer LNCaP cells by regulating androgen receptor gene [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 10-17.
[10]	CHEN Lifang, WANG Bo, WANG Weirong. Research advances of histone deacetylase 3 in cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 88-97.
[11]	XU Lina, LI Yue, PENG Jinyong. microRNA and drug-induced liver injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 803-809.
[12]	JIANG Bingbing. Research progress on microRNAs in Huntington's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 677-685.
[13]	FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
[14]	ZHU Linjia, YUAN Shaofei, SHANGGUAN Zongxiao, CI Xiao, ZHAO Renguo, LI Yuping. Ultrasound-microbubbles mediated microRNA-449a inhibits lung cancer cell growth via the regulation of Notch1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1385-1393.
[15]	WU Juan, WU Yongjun, LI Zhi, ZENG Chang, LI Zhenfeng, TANG Yi, LU Miao, ZHANG Xuechun, ZHANG Wanyong, WANG Danhui, LIU Chenrui. Epigenetic regulation of Dapper family proteins in cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1434-1440.